-
EP4069693
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4069693
| EP4069693 - HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES [Right-click to bookmark this link] | |||
| Former [2022/41] | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ||
| [2023/42] | Status | The patent has been granted Status updated on 16.02.2024 Database last updated on 20.12.2024 | |
| Former | Grant of patent is intended Status updated on 11.10.2023 | ||
| Former | Examination is in progress Status updated on 30.03.2023 | ||
| Former | Request for examination was made Status updated on 09.09.2022 | ||
| Former | The international publication has been made Status updated on 11.06.2021 | ||
| Former | unknown Status updated on 14.12.2020 | Most recent event Tooltip | 01.11.2024 | Lapse of the patent in a contracting state New state(s): PL, RO, SK | published on 04.12.2024 [2024/49] | Applicant(s) | For all designated states F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2022/41] | Inventor(s) | 01 /
CHEN, Jianguo c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720, Cailun Road Shanghai, 201203 / CN | 02 /
DEY, Fabian c/o F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | 03 /
XU, Hongtao c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720, Cailun Road Shanghai, 201203 / CN | 04 /
ZHANG, Weixing c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720, Cailun Road Shanghai, 201203 / CN | 05 /
ZHU, Wei c/o Roche R&D Center (China) Ltd. Building No. 5 Lane 720, Cailun Road Shanghai, 201203 / CN | [2022/41] | Representative(s) | Belkacemi, Doria F. Hoffmann-La Roche AG Grenzacherstrasse 124 4070 Basel / CH | [2022/41] | Application number, filing date | 20819661.8 | 01.12.2020 | [2022/41] | WO2020EP83996 | Priority number, date | WO2019CN122716 | 03.12.2019 Original published format: PCT/CN2019/122716 | [2022/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021110614 | Date: | 10.06.2021 | Language: | EN | [2021/23] | Type: | A1 Application with search report | No.: | EP4069693 | Date: | 12.10.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.06.2021 takes the place of the publication of the European patent application. | [2022/41] | Type: | B1 Patent specification | No.: | EP4069693 | Date: | 20.03.2024 | Language: | EN | [2024/12] | Search report(s) | International search report - published on: | EP | 10.06.2021 | Classification | IPC: | C07D471/04, C07D519/00, A61P37/00, A61P37/02, A61K31/497 | [2022/41] | CPC: |
C07D471/04 (EP,US);
A61P37/00 (EP);
A61P37/02 (EP);
C07D519/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/41]
| Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | HYDROPYRIDO[1,2-ALPHA]PYRAZINVERBINDUNGEN ZUR BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN | [2022/41] | English: | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | [2023/42] | French: | COMPOSÉS D'HYDROPYRIDO[1,2-ALPHA]PYRAZINE POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES | [2023/42] |
| Former [2022/41] | HYDROPYRIDO[1,2-ALPHA]PYRAZINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ||
| Former [2022/41] | COMPOSÉS D'HYDROPYRIDO[1,2-ALPHA]PYRAZINE POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE | Entry into regional phase | 04.07.2022 | National basic fee paid | 04.07.2022 | Designation fee(s) paid | 04.07.2022 | Examination fee paid | Examination procedure | 04.07.2022 | Examination requested [2022/41] | 04.07.2022 | Date on which the examining division has become responsible | 11.01.2023 | Amendment by applicant (claims and/or description) | 29.03.2023 | Despatch of a communication from the examining division (Time limit: M06) | 11.09.2023 | Reply to a communication from the examining division | 12.10.2023 | Communication of intention to grant the patent | 08.02.2024 | Fee for grant paid | 08.02.2024 | Fee for publishing/printing paid | 08.02.2024 | Receipt of the translation of the claim(s) | Fees paid | Renewal fee | 09.12.2022 | Renewal fee patent year 03 | 19.12.2023 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | CZ | 20.03.2024 | ES | 20.03.2024 | HR | 20.03.2024 | PL | 20.03.2024 | RO | 20.03.2024 | SK | 20.03.2024 | SM | 20.03.2024 | NO | 20.06.2024 | RS | 20.06.2024 | GR | 21.06.2024 | IS | 20.07.2024 | [2024/49] |
| Former [2024/48] | CZ | 20.03.2024 | |
| ES | 20.03.2024 | ||
| HR | 20.03.2024 | ||
| SM | 20.03.2024 | ||
| NO | 20.06.2024 | ||
| RS | 20.06.2024 | ||
| GR | 21.06.2024 | ||
| IS | 20.07.2024 | ||
| Former [2024/47] | HR | 20.03.2024 | |
| SM | 20.03.2024 | ||
| NO | 20.06.2024 | ||
| RS | 20.06.2024 | ||
| GR | 21.06.2024 | ||
| IS | 20.07.2024 | ||
| Former [2024/46] | HR | 20.03.2024 | |
| NO | 20.06.2024 | ||
| RS | 20.06.2024 | ||
| GR | 21.06.2024 | ||
| IS | 20.07.2024 | ||
| Former [2024/35] | HR | 20.03.2024 | |
| NO | 20.06.2024 | ||
| RS | 20.06.2024 | ||
| GR | 21.06.2024 | ||
| Former [2024/33] | NO | 20.06.2024 | Cited in | International search | [A]WO2015057655 (EISAI R&D MAN CO LTD [JP], et al) [A] 1-19 * abstract * * figure 3; table - *; | [A]WO2015057659 (EISAI R&D MAN CO LTD [JP], et al) [A] 1-19 * abstract * * figure 6; table - *; | [A]WO2017106607 (MERCK PATENT GMBH [DE], et al) [A] 1-19 * abstract * * pages 38-165; table 1; compounds 1-591 *; | [A]WO2018031434 (MERCK PATENT GMBH [DE], et al) [A] 1-19 * abstract * * pages 28-43; table 1; compounds 1-160 *; | [YP]WO2020020800 (HOFFMANN LA ROCHE [CH], et al) [YP] 1-19* abstract *; | [YP]WO2020207991 (HOFFMANN LA ROCHE [CH], et al) [YP] 1-19 * abstract * | by applicant | - NAVARRA, S. V. et al., Lancet, (20110000), vol. 377, page 721 | - KRIEG, A. M. et al., Immunol. Rev., (20070000), vol. 220, page 251 | - JIMENEZ-DALMARONI, M. J. et al., Autoimmun Rev, (20160000), vol. 15, page 1 | - CHEN, J. Q. et al., Clinical Reviews in Allergy & Immunology, (20160000), vol. 50, page 1 | - Acc. Chem. Res., (19980900), vol. 31, pages 805 - 818 | - Chem. Rev., (20160000), vol. 116, pages 12564 - 12649 | - Topics in Current Chemistry, (20020000), vol. 219, pages 131 - 209 | - Acc. Chem. Res., (19980000), vol. 31, pages 805 - 818 | - Chem. Eur. J., (20160000), vol. 22, pages 6253 - 6257 | - J. Org. Chem., (20140000), vol. 79, pages 328 - 338 | - CAS, no. 4983-28-2 | - REDFERN WSCARLSSON LDAVIS ASLYNCH WGMACKENZIE IPALETHORPE SSIEGL PKSTRANG ISULLIVAN ATWALLIS R, "Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development", Cardiovasc. Res., (20030000), vol. 58, doi:10.1016/S0008-6363(02)00846-5, pages 32 - 45, XP004722301 DOI: http://dx.doi.org/10.1016/S0008-6363(02)00846-5 | - SANGUINETTI MCTRISTANI-FIROUZI M, "hERG potassium channels and cardiac arrhythmia", Nature, (20060000), vol. 440, pages 463 - 469 | - WEBSTER RLEISHMAN DWALKER D, "Towards a drug concentration effect relationship for QT prolongation and torsades de pointes", Curr. Opin. Drug Discov. Devel., (20020000), vol. 5, pages 116 - 26 |